Skip to content
Home » HPV vaccine after cervical pre-cancer surgery reduces recurrence

HPV vaccine after cervical pre-cancer surgery reduces recurrence


For years, the HPV vaccine has been administered usually before sexual debut; however, a new study shows that there is a dramatic reduction in the risk for cervical lesions when the vaccine is given after surgery.

Cervical conization (surgical excision) is an effective treatment for precancerous cervical lesions. Unfortunately, recurrence of the lesions has been a challenge for treatment, especially among women with positive surgical margins, where not all abnormal tissue may have been removed.

This post will examine this new study about the effectiveness of the HPV vaccine given after cervical surgery.

HPV and the HPV vaccines

I know I cut and paste this section into every article I write about HPV vaccines, but it’s the first step to HPV vaccine myth debunking. Some readers may be researching the vaccine for the first time, and they can find out how the HPV vaccine reduces cancer risks.

However, I try to update this section when necessary with new information about either the disease or the vaccine. If you’ve read this section 47 times, skip to the next section where I discuss the key points of this article.

Genital and oral human papillomavirus (HPV) infections are the most common sexually transmitted infections (STIs) in the USA.  HPV is generally transmitted from personal contact during vaginal, anal, or oral sex.

It is critical to note that there are more than 150 strains or subtypes of HPV that can infect humans; however, only 40 of these strains are linked to one or more different cancers. Moreover, of those 40 strains, most are fairly rare.

Although the early symptoms of HPV infections aren’t serious and many HPV infections resolve themselves without long-term harm, HPV infections are causally linked to many types of cancers in men and women. According to current medical research, here are some of the cancers that are linked to HPV:

In addition, there is some evidence that HPV infections are causally linked to skin and prostate cancers. The link to skin cancer is still preliminary, but there is much stronger evidence that HPV is linked to many prostate cancers.

HPV is believed to cause nearly 5% of all new cancers across the world, making it almost as dangerous as tobacco in that respect. According to published research, roughly 42 million persons in the USA are infected with disease-associated HPV, and 13 million persons acquire a new infection each year.

Each year in the United States, about 47,984 new cases of cancer are found in parts of the body where human papillomavirus (HPV) is often found — 26,280 among females, and 21,704 among males. 

Most individuals don’t even know they have the infection until the onset of cancer. The CDC states that over 37,800 HPV-related cancers are diagnosed in the USA every year. It is probably several times that amount worldwide.

There were two HPV vaccines on the world market before 2014. GSK, also known as GlaxoSmithKline, produced Cervarix, a bivalent vaccine that protects only against two HPV strains. Cervarix has been withdrawn from the US market (although available in many other markets) because of competition from the quadrivalent, which immunizes against four different HPV strains, and the 9-valent, which protects against nine HPV strains, Gardasil vaccines.

Merck manufactures Gardasil, probably the most popular HPV vaccine in the world. The first version of the vaccine, quadrivalent Gardasil, targets the two HPV genotypes known to cause about 70% of cervical cancer and two other HPV genotypes that cause genital warts. In Europe and other markets, Gardasil is known as Silgard.

The newer Gardasil 9, approved by the FDA in 2014, is a 9-valent vaccine that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It targets the four HPV strains found in the quadrivalent version, along with five additional ones that are linked to cervical and other HPV-related cancers. Both versions of Gardasil are prophylactic, meant to be given to females or males before they become exposed to possible HPV infection through intimate contact.

Gardasil is one of the easiest and best ways to prevent a few dangerous and, to abuse the definition slightly, common cancers that afflict men and women. Without a doubt, the HPV vaccine prevents cancer.

In the United States, the Advisory Committee on Immunization Practices (ACIP) currently recommends that preteen girls and boys aged 11 or 12 receive the HPV vaccine. The HPV vaccine is also recommended for teenage girls and young women up to the age of 26 who did not receive it when they were younger, and boys and young men up to the age of 21.

HPV is a sexually transmitted disease. HPV causes 37,800 cancers a year in the USA alone. The HPV vaccine prevents one from becoming infected by HPV, which means you are protected from these cancers.

HPV vaccine cervical cancer surgery

HPV vaccine after cervical cancer surgery study

In a paper published on 3 June 2025 in The Lancet Regional Health Europe, Marek Petráš, MSc, PhD, Department of Epidemiology and Biostatistics at the Third Faculty of Medicine, Charles University, Prague, Czech Republic, and colleagues developed a cohort study that used data from one of the central laboratories in the country. The data covered approximately 33% of women undergoing national cervical cancer screening, or over 10,000 Czech women.

This study included women treated for CIN2+ — CIN is cervical intraepithelial neoplasm, and 2+ refers to moderate to marked dysplasia. This cohort had received either a prophylactic HPV vaccine (which was available through the country’s national immunization program since 2011) or a post-surgery HPV vaccine.

Here are the key results:

  • Women who received the HPV vaccine after surgery (conization) experienced a 74% reduction in recurrent high-grade cervical lesions (CIN2+).
  • Women vaccinated during adolescence had a 62% reduction in recurrence risk.
  • Women who received the HPV vaccine immediately after surgery had a 89% reduction in recurrence in just 6 months, when relapse is most common.

The authors concluded:

Regardless of timing, HPV vaccination has a beneficial long-term effect in lowering the risk of CIN2+ recurrence. Despite the greater reduction in relapse achieved by post-excision vaccination, the difference compared with the prophylactic one was not statistically significant. The most pronounced benefit was observed within the first six months post-conisation, particularly in women with a positive cone margin.

Summary

This study provides incredibly important evidence that getting the HPV vaccine after pre-cancer surgery greatly reduces the risk of recurrence of CIN2+. But this is not the only evidence for the value of HPV vaccination post-surgery.

The American Society for Colposcopy and Cervical Pathology supports the possible benefit of adjuvant HPV vaccination during shared decision-making for previously unvaccinated individuals aged 27 to 45 years who are undergoing treatment for CIN2+.

I am not sure if there is any better evidence for the value of the HPV vaccine. Even if you’re an adult and develop cervical lesions, you should get the HPV vaccine soon after surgery. It might save your life.

The HPV vaccine is truly one of the best cancer vaccines.

Citations

symmetrical photography of clouds covered blue sky
Photo by James Wheeler on Pexels.com

Help the Skeptical Raptor keep writing about cancer vaccines

There are four ways you can help contribute to keeping this website running at full speed:

  1. GoFundMe.
  2. Contributing via Patreon.
  3. Buying on Amazon.
  4. Sharing this article on Social Media.

Don’t miss each new article!

We don’t spam! Read our privacy policy for more info.

Liked it? Take a second to support Michael Simpson on Patreon!
Become a patron at Patreon!


Discover more from Skeptical Raptor

Subscribe to get the latest posts sent to your email.

Discover more from Skeptical Raptor

Subscribe now to keep reading and get access to the full archive.

Continue reading